Repare Therapeutics Shares Dip After Updated RP-3500 Data In Solid Tumors

  • Repare Therapeutics Inc RPTX presented updated data from its ongoing Phase 1/2 TRESR trial of RP-3500 for solid tumors with specific synthetic-lethal genomic alterations.
  • The data were featured at the AACR Annual Meeting included monotherapy Phase 1 (Module 1) results from 120 patients.
  • RP-3500 monotherapy appeared to be safe and well-tolerated. Mild to moderate anemia was the most common treatment-related adverse event. 
  • RP-3500 monotherapy resulted in durable clinical benefit across tumor types and genomic alterations. Overall clinical benefit rate (CBR) for all patients was 43% and 47% after PARP inhibitor (PARPi) failure.
  • Related: Repare Therapeutics Highlights Early RP-3500 Data In Solid Tumor Patients.
  • In the ovarian cancer cohort (n = 20), the overall response (OR) was 25%, including one complete response (CR) and three partial responses (PR). 
  • CBR was 75%, and median progression-free survival (mPFS) was 35 weeks.
  • Clinical benefit was also observed in patients with tumors harboring BRCA1 and BRCA2 genomic alterations (n = 37). ORR was 14%. 
  • CBR was 43% with an mPFS of 15 weeks in the BRCA1/2 population; in patients specifically with BRCA1 mutations, the CBR was 48%.
  • In patients with ATM loss-of-function (LOF) tumors (n = 34), ORR was 9% including one confirmed/unconfirmed response, and two prostate-specific antigen (cPSA) responses. 
  • CBR in patients with ATM LOF was 44%, with mPFS of 17 weeks.
  • Price Action: RPTX shares are down 4.82% at $9.87 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsPhase 1 TrialPhase 2 Trialwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!